Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | protein tyrosine kinase 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Schistosoma japonicum | Protein tyrosine kinase 2 beta, putative | Get druggable targets OG5_130513 | All targets in OG5_130513 |
Loa Loa (eye worm) | TK/FAK protein kinase | Get druggable targets OG5_130513 | All targets in OG5_130513 |
Schistosoma japonicum | expressed protein | Get druggable targets OG5_130513 | All targets in OG5_130513 |
Schistosoma japonicum | expressed protein | Get druggable targets OG5_130513 | All targets in OG5_130513 |
Echinococcus granulosus | protein tyrosine kinase | Get druggable targets OG5_130513 | All targets in OG5_130513 |
Echinococcus multilocularis | protein tyrosine kinase | Get druggable targets OG5_130513 | All targets in OG5_130513 |
Brugia malayi | Protein kinase domain containing protein | Get druggable targets OG5_130513 | All targets in OG5_130513 |
Schistosoma mansoni | tyrosine kinase | Get druggable targets OG5_130513 | All targets in OG5_130513 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | pteridine reductase 1 | 0.0208 | 0 | 0.5 |
Echinococcus granulosus | protein tyrosine kinase | 0.0305 | 0.0339 | 1 |
Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.3074 | 1 | 1 |
Schistosoma mansoni | tyrosine kinase | 0.0305 | 0.0339 | 1 |
Onchocerca volvulus | 0.0208 | 0 | 0.5 | |
Loa Loa (eye worm) | TK/FAK protein kinase | 0.0309 | 0.0351 | 1 |
Trypanosoma brucei | beta-ketoacyl-ACP reductase | 0.0208 | 0 | 0.5 |
Echinococcus multilocularis | protein tyrosine kinase | 0.0305 | 0.0339 | 1 |
Trypanosoma cruzi | beta-ketoacyl-ACP reductase | 0.0208 | 0 | 0.5 |
Brugia malayi | Protein kinase domain containing protein | 0.0309 | 0.0351 | 1 |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.3074 | 1 | 1 |
Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.3074 | 1 | 1 |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.3074 | 1 | 1 |
Trypanosoma brucei | pteridine reductase 1 | 0.0208 | 0 | 0.5 |
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.3074 | 1 | 1 |
Trypanosoma brucei | oxidoreductase-like protein | 0.0208 | 0 | 0.5 |
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.3074 | 1 | 1 |
Trypanosoma cruzi | oxidoreductase-like protein, putative | 0.0208 | 0 | 0.5 |
Trichomonas vaginalis | hypothetical protein | 0.3074 | 1 | 0.5 |
Leishmania major | oxidoreductase-like protein | 0.0208 | 0 | 0.5 |
Onchocerca volvulus | 0.0208 | 0 | 0.5 | |
Entamoeba histolytica | 3-oxoacyl-(acyl-carrier protein) reductase, putative | 0.0208 | 0 | 0.5 |
Leishmania major | dehydrogenase/oxidoreductase-like protein | 0.0208 | 0 | 0.5 |
Trypanosoma cruzi | beta-ketoacyl-ACP reductase | 0.0208 | 0 | 0.5 |
Leishmania major | 3-oxoacyl-ACP reductase, putative | 0.0208 | 0 | 0.5 |
Leishmania major | dehydrogenase/oxidoreductase-like protein | 0.0208 | 0 | 0.5 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.3074 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 1 nM | BindingDB_Patents: Enzyme Assay. This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)). | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.